Nkarta (NASDAQ:NKTX) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded Nkarta from “sell” to “strong sell,” despite the broader analyst consensus remaining “Moderate Buy” with a $11.20 average price target.
• Nkarta shares opened at $2.33, near the lower end of their $1.70–$3.72 yearly range, while the company reported a quarterly loss of $0.54 per share—$0.18 worse than estimates.
• Institutional investors and hedge funds own approximately 80.54% of Nkarta’s stock, while analysts expect the company to post a $1.54-per-share loss for the current fiscal year.

Nkarta (NASDAQ:NKTX - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "sell" rating to a "strong sell" rating in a report released on Saturday.

NKTX has been the subject of several other research reports. Evercore set a $9.00 target price on shares of Nkarta in a research note on Monday, May 18th. HC Wainwright decreased their price objective on shares of Nkarta to $14.00 and set a "buy" rating on the stock in a report on Tuesday. Stifel Nicolaus lowered their price objective on shares of Nkarta from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Friday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Nkarta in a research report on Wednesday, June 24th. Finally, TD Cowen began coverage on shares of Nkarta in a report on Tuesday, June 23rd. They issued a "buy" rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $11.20.

Nkarta Price Performance

Shares of NKTX stock opened at $2.33 on Friday. Nkarta has a 1-year low of $1.70 and a 1-year high of $3.72. The company has a market cap of $166.87 million, a price-to-earnings ratio of -1.48 and a beta of 0.93. The stock has a 50 day simple moving average of $2.64 and a 200-day simple moving average of $2.58.

Nkarta (NASDAQ:NKTX - Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.18). Analysts anticipate that Nkarta will post -1.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Nkarta

Institutional investors and hedge funds have recently modified their holdings of the company. Abel Hall LLC acquired a new stake in shares of Nkarta during the 4th quarter worth about $27,000. The Manufacturers Life Insurance Company purchased a new position in Nkarta in the first quarter valued at approximately $30,000. Pallas Capital Advisors LLC acquired a new stake in Nkarta during the second quarter worth approximately $31,000. Dynamic Technology Lab Private Ltd acquired a new stake in Nkarta during the fourth quarter worth approximately $37,000. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of Nkarta during the 2nd quarter worth approximately $81,000. Institutional investors and hedge funds own 80.54% of the company's stock.

Key Headlines Impacting Nkarta

Here are the key news stories impacting Nkarta this week:

• Positive Sentiment: Stifel maintains a bullish view: Stifel Nicolaus lowered its price target from $11 to $10 but initiated or reaffirmed a “Buy” rating. The revised target still implies approximately 329% upside from the referenced $2.33 share price, providing a positive catalyst for Nkarta (NKTX). Ticker Report article
• Negative Sentiment: HC Wainwright cut earnings estimates across the forecast period: The firm reduced its EPS forecasts for the third and fourth quarters of 2026 to losses of $0.46 and $0.48, respectively, and lowered its full-year estimates to losses of $1.86 in 2026, $2.26 in 2027, $1.76 in 2028, $1.53 in 2029 and $1.23 in 2030. These revisions indicate expectations for deeper or more persistent losses, which may pressure NKTX despite HC Wainwright retaining its “Buy” rating and $14 price target. MarketBeat analyst estimates article

Nkarta Company Profile

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company's platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta's lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source